Program
hyaluronidase (human recombinant)
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.
Drug pageHyaluronidase (human recombinant): every studyMany companies study it; this page follows only the 57 they lead. All 69 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenxits history only | 2211 open or running | phase 4since Oct 7, 2024 | Feb 20, 2020 | Mar 2027phase 2 · NCT06655155 |
| Halozyme Therapeuticsits history only | 200 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Takedaits history only | 60 open or running | phase 3since Dec 23, 2008 | Oct 29, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 42 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | Aug 31, 2029phase 2 · NCT07503340 |
| Baxter Healthcareits history only | 30 open or running | phase 4since Dec 10, 2008 | Dec 10, 2008 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Aug 6, 2015 | Aug 6, 2015 | none ahead |
Also a collaborator on its studies: BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2015First study: phase 1 study in Multiple MyelomaFirst studyNCT02519452 · 120 enrolled · United States, Denmark, France and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Johnson & Johnson leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02519452Multiple Myeloma · United States, Denmark, France and more | 1 | Completed | Dec 13, 2017 | 120 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “rHuPH20”, 5 entries
- “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
- “recombinant human hyaluronidase”, 3 entries
Codes read as this program: RHUPH20.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 6 studies
- Myasthenia Gravis, 5 studies
- Primary Immunodeficiency Diseases, 4 studies
- Dehydration, 4 studies
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.